Pharmacare News Bulletins

Nova Scotia Pharmacare

Pharmacare News Bulletins

The Pharmacare News Bulletins, which are mailed to pharmacies and physicians, are listed below. They are an important source of information as they provide timely information on recent changes to the Pharmacare Programs.

Please continue to refer to the Pharmacare News Bulletins to stay current with Formulary and Pharmacare Program updates.

Latest Issues

July Bulletin Vol. 20 – 09
Updates to the Nova Scotia Pharmacy Guide. New Exception Status Benefits: Elelyso (taliglucerase alfa), Mavenclad (cladribine), Mictoryl (propiverine hydrochloride), VPRIV (velaglucerase alfa)

June Bulletin Vol. 20 – 08
Reinstating Prescription Renewal Limits.
Extension of Removal of In-Person Requirement for Assessment and Prescribing.
Change in Billing Process for Therapeutic Substitution and Prescription Adaptation Services.
New Benefit: Spanish Labelled Jamp-Salbutamol.
New Exception Status Benefits: Erleada (apalutamide), Radicava (edaravone)

May Bulletin Vol. 20 – 07
New Exception Status Benefits: Sublocade (buprenorphine), Cotellic (cobemetinib), Cabometyx (cabozantinib), Xeljanz XR (tofacitinib)

May Bulletin Vol. 20 – 06
Update on COVID-19 Pharmacy Measures

April Bulletin Vol. 20 – 05
Coverage of Extra Dispensing Fees

April Bulletin Vol. 20 – 04
Extension of Coverage for Exception Status Medications. New Exception Status Benefits: Ocrevus (ocrelizumab), Fulphila (pegfilgrastim), Lapelga (pegfilgrastim)

March Bulletin Vol. 20 – 03
Public funding for prescription renewal services available effective 19 March 2020. In-person requirement is waived for assessment and prescribing. Adjustment to days supply for dispensing to pharmacare beneficiaries during COVID-19 outbreak.

Latest Issue

June Bulletin Vol. 20 – 05
New Exception Status Benefits: Erleada (apalutamide), Radicava (edaravone)

May Bulletin Vol. 20 – 04
New Exception Status Benefits: Sublocade (buprenorphine), Cotellic (cobemetinib), Cabometyx (cabozantinib), Xeljanz XR (tofacitinib)

April Bulletin Vol. 20 – 03
Extension of Coverage for Exception Status Medications. New Exception Status Benefits: Ocrevus (ocrelizumab), Fulphila (pegfilgrastim), Lapelga (pegfilgrastim)

February Bulletin Vol. 20 – 02
New Exception Status Benefits: Cubicin RF (daptomycin), Duodopa (levodopa/ carbidopa), Glatect (glatiramer acetate), Tygacil (tigecycline), Zerbaxa (ceftolozane/ tazobactam)

January Bulletin Vol. 20 – 01
New Exception Status Benefits: Skyrizi (risankizumab), Probuphine (buprenorphine hydrochloride)